Global Prostate Cancer Biomarkers Market Size To Exceed USD 14.48 Billion by 2033: Market Study Report

Global Prostate Cancer Biomarkers Market Size To Exceed USD 14.48 Billion by 2033

According to a research report published by Spherical Insights & Consulting, The Global Prostate Cancer Biomarkers Market Size is Expected to Grow from USD 4.14 Billion in 2023 to USD 14.48 Billion by 2033, at a CAGR of 13.34% during the forecast period 2023-2033.  

The global prostate cancer biomarkers market refers to the industry that finds, creates, and markets biological indicators for prostate cancer detection, diagnosis, and monitoring. By contributing to early detection, evaluating the development of the disease, and directing avenues for therapy, these biomarkers enhance patient outcomes and promote individualized cancer care strategies. Key driving factors for the growth of the prostate cancer biomarkers market include the growing demand for non-invasive diagnostic techniques that provide tailored therapy, improving patient outcomes and reducing healthcare costs, expanding awareness of early detection, and advances in biomarker research. However, the lack of standardized testing procedures, high testing prices, restricted accessibility in low-income areas, and variations in biomarker accuracy all limit the reliability and extensive clinical acceptance of the test.

The protein biomarkers segment accounted for the largest revenue share in 2023 and is projected to grow at a significant CAGR during the forecast period.

On the basis of type, the global prostate cancer biomarkers market is divided into genetic biomarkers, protein biomarkers, cell-based biomarkers, and metabolomic biomarkers. Among these, the protein biomarkers segment accounted for the largest revenue share in 2023 and is projected to grow at a significant CAGR during the forecast period. The segment growth is attributed to the increasing demand for individualized therapy, enhanced diagnostic precision given by technology, including mass spectrometry, and a rise in clinical use for prostate cancer early detection and monitoring.

The screening & early detection segment accounted for the highest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

On the basis of application, the global prostate cancer biomarkers market is divided into screening & early detection, diagnosis & risk stratification, prognosis & treatment monitoring, and companion diagnostics. Among these, the screening & early detection segment accounted for the highest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. The segment growth is driven because of an increased emphasis on early diagnosis to enhance the outcome of prostate cancer treatment, the growing use of biomarker-based diagnostics, and alternative methods like liquid biopsies.

North America is anticipated to hold the largest share of the global prostate cancer biomarkers market over the predicted timeframe.

North America is anticipated to hold the largest share of the global prostate cancer biomarkers market over the predicted timeframe. The regional market growth is driven by the promotion of precision medicine, strong regulatory support, and the increasing recognition of biomarkers for diagnosis and treatment, all encourage broader adoption of advanced testing across healthcare systems.

Asia Pacific is expected to grow at the fastest CAGR in the global prostate cancer biomarkers market during the forecast period. The regional market growth can be attributed to increased funding for healthcare, improved access to innovative diagnostics, and government programs that encourage precision therapies. Biomarker innovation and adoption in the region are being driven by increased development and research, particularly in China and Japan.

Company Profiling 

Major vendors in the global prostate cancer biomarkers market are Exact Sciences Corporation, Myriad Genetics, Inc., Bio-Techne, ExoDx, OPKO Health, Inc., mdxhealth, Veracyte, Inc., Beckman Coulter, Inc., Nucleix, DiaCarta, and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In December 2024, PanGIA Biotech, in collaboration with Canary Oncoceutics, launched the PanGIA Prostate Assay in India, the world’s first AI-integrated, urine-based liquid biopsy for prostate cancer detection. This non-invasive test aims to improve early detection and patient outcomes in India, where late-stage diagnoses are prevalent.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global prostate cancer biomarkers market based on the below-mentioned segments: 

Global Prostate Cancer Biomarkers Market, By Type

• Genetic Biomarkers
• Protein Biomarkers
• Cell-based Biomarkers
• Metabolomic Biomarkers

Global Prostate Cancer Biomarkers Market, By Application

• Screening & Early Detection
• Diagnosis & Risk Stratification
• Prognosis & Treatment Monitoring
• Companion Diagnostics

Global Prostate Cancer Biomarkers Market, Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa